Abstract
Most autoimmune diseases (ADs) are still associated with high morbidity and mortality despite the use of a wide range of drugs that can delay their progression, control their symptoms, but never bring about a complete cure. This failure has aroused interest in new forms of monoclonal antibody-based experimental immunotherapy (IT), aiming at targeting cellular antigens or cytokines involved in the pathogenesis of ADs. The first part of this review offers a general overview of the molecular mechanisms that mediate the immune response and the molecule regarded as potential IT targets. A critical evaluation will then be made of some forms of IT, with particular emphasis on TNF-α and CD20-blocking reagents. Lastly an account will be given of active IT whereby an endogenous response against antigens regarded as the target of passive IT can be induced by anti-idiotype or peptides.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Prete, M., Perosa, F., Favoino, E. et al. Biological therapy with monoclonal antibodies: a novel treatment approach to autoimmune disease. Clin. Exper.Med. 5, 141–160 (2005). https://doi.org/10.1007/s10238-005-0080-5
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10238-005-0080-5